The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care.
The new algorithm from Implicityevaluates implantable device data and monitors patients for changes that suggest they could experience severe heart failure symptoms in the near future. It was designed to alert clinicians up to weeks in advance.
“This type of screening could be used to identify individuals who would benefit from statin medication but are currently untreated," one specialist said. The full analysis will be presented at RSNA 2022 in Chicago.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."
